Claudia Alicata

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Systematic Review

Dna Methylation

Inflammatory Response

Top Venues

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Piera Bontempo, Cecilia Surace, Lucia Menale, Claudia Alicata, Gemma D'Elia, Anna Cristina Tomaiuolo, Daniele Minervino, Elisa Lorefice, Antonio Novelli
A De Novo CaSR Missense Variant in Combination with Two Inherited Missense Variants in CFTR and SPINK1 Detected in a Patient with Chronic Pancreatitis. Biomedicines 12 (6) (2024)
Piera Bontempo, Cecilia Surace, Lucia Menale, Claudia Alicata, Gemma D'Elia, Anna Cristina Tomaiuolo, Daniele Minervino, Elisa Lorefice, Antonio Novelli
A De Novo CaSR Missense Variant in Combination with Two Inherited Missense Variants in CFTR and SPINK1 Detected in a Patient with Chronic Pancreatitis. Biomedicines 12 (6) (2024)
Irene Veneziani, Claudia Alicata, Lorenzo Moretta, Enrico Maggi
The Latest Approach of Immunotherapy with Endosomal TLR Agonists Improving NK Cell Function: An Overview. Biomedicines 11 (1) (2022)
Nadine Landolina, Francesca Romana Mariotti, Tiziano Ingegnere, Claudia Alicata, Biancamaria Ricci, Andrea Pelosi, Irene Veneziani, Bruno Giuseppe Azzarone, Cecilia Garlanda, Alberto Mantovani, Alessandro Moretta, Enrico Maggi
IL-1R8 silencing improves the anti-tumor function of freshly isolated human NK cells. Journal for immunotherapy of cancer 10 (3) (2022)
Irene Veneziani, Claudia Alicata, Lorenzo Moretta, Enrico Maggi
The Latest Approach of Immunotherapy with Endosomal TLR Agonists Improving NK Cell Function: An Overview. Biomedicines 11 (1) (2022)
Michela Falco, Raffaella Meazza, Claudia Alicata, Paolo Canevali, Aura Muntasell, Cristina Bottino, Alessandro Moretta, Daniela Pende, Miguel López-Botet
Epitope characterization of a monoclonal antibody that selectively recognizes KIR2DL1 allotypes. HLA 100 (2) (2022)